25H-NBOMe
25H-NBOMe, also known as NBOMe-2C-H, is a derivative of the phenethylamine hallucinogen 2C-H, which acts as a highly potent full agonist for the human 5-HT2A receptor.
Use and effects
The active dose range of 25H-NBOMe in humans has not been reported and hence is unknown. This is in notable contrast to many other NBOMe drugs.Toxicity and harm potential
Neurotoxic and cardiotoxic actions
Emergency treatment
Interactions
Pharmacology
Pharmacodynamics
25H-NBOMe acts as an agonist of the serotonin 5-HT2 receptors.Its affinity for the serotonin 5-HT2A receptor was 133-fold higher than that of 2C-H and 24-fold higher than that of 25H-NB, whereas it was 4-fold lower than that of 2C-I and 64-fold lower than that of 25I-NBOMe. In terms of activational potency at the receptor, the drug's potency was 67-fold higher than that of 2C-H, whereas it was 6-fold lower than that of 2C-I and 35-fold lower than that of 25I-NBOMe. Hence, unlike other NBOMe drugs, 25H-NBOMe appears to have affinity and activational potency at the serotonin 5-HT2A receptor more in line with the 2C psychedelics like 2C-I and much lower than NBOMe drugs like 25I-NBOMe.
25H-NBOMe produces hyperlocomotion, a stimulant-like effect, and the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. Its potency in inducing the head-twitch response was variably lower than that of other NBOMe drugs like 25I-NBOMe and 25B-NBOMe. Conversely, its potency in inducing hyperlocomotion was about the same as that of 25I-NBOMe and 25C-NBOMe. The drug has also been found to produce antidepressant-like effects in rodents. 25H-NBOMe has shown reinforcing effects in rodents. This included conditioned place preference and self-administration.